Navigation Links
Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference

- New Approach to Targeting the Tumor Microenvironment -

SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced new pre-clinical findings on the treatment of prostate cancer models at the American Association for Cancer Research (AACR) conference. Halozyme is investigating its Pegylated-rHuPH20 enzyme (PEGrHuPH20) as a candidate for the systemic treatment of tumors rich in hyaluronan (HA) in combination with chemotherapy.

The studies explored the physiologic responses to enzymatic removal of HA-based matrices surrounding tumor cells in the tumor microenvironment of prostate tumors following systemic administration of its PEGrHuPH20 pre-clinical candidate. In animal pharmacokinetic models, PEGrHuPH20 demonstrated a more than 2,000-fold increase in plasma half-life compared to the unmodified enzyme. Prostate tumors were grown around the bone as a model of elevated interstitial fluid pressure (IFP). Treatment commenced when tumors had reached approximately 500 mm3 in size and pressure within the tumor had reached 30-40 mm Hg.

The objectives of these studies were to determine whether HA-dependent pericellular matrices produced in vitro and in vivo by hormone refractory prostate cancer cell line could be enzymatically depleted in prostate carcinoma xenografts following intravenous (IV) administration of the PEGrHuPH20 enzyme. The dose dependent effects of systemic enzyme treatment were evaluated by a combination of direct micropressure measurements, magnetic resonance imaging (MRI), ultrasound, immunohistochemistry, and determination of tumor water content. A summary of findings is as follows:

-- Prostate carcinoma cells assembled large pericellular coats in vitro

that collapsed in the presence of the hyaluronidase enzyme, rHuPH20.

Similar pericellular matrices containing HA were also assembled in vivo

following inoculation of tumors around the bone in mice.

-- PEGrHuPH20 significantly reduced tumor IFP in a dose dependent fashion,

achieving more than 85% reduction in IFP following IV administration.

Peritumoral HA remained depleted over 3 days after a single dose of


-- Consistent with the histologic collapse of pericellular HA surrounding

the tumor cells, tumor water content significantly decreased over 3

days, consistent with changes detected in the tumor by MRI and IFP


-- Furthermore, a 3.5-fold selective increase in tumor vascular volume was

achieved within 8 hours post-dosing as a result of vascular

decompression of blood vessels within the tumor, which was confirmed by

histology and ultrasound.

"These findings represent significant advancements towards our goal of understanding the role of HA in the tumor microenvironment and mechanism of action of PEGrHuPH20" said Gregory Frost, PhD, Halozyme's Vice President and Chief Scientific Officer. "By selectively decompressing tumor vessels, we may significantly improve tumor exposure and responses to chemotherapy regimens. These findings have facilitated our efficacy studies in combination with selected chemotherapy agents, which will be presented later this year as part of our overall development strategy for this new compound."

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, oncology and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the pre-clinical results of the company's pegylated rHuPH20 enzyme) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

Halozyme Contact Media Contacts

David A. Ramsay Karen Sparks / Joleen Schultz

Chief Financial Officer Mentus

(858) 704-8260 (858) 455-5500, x275/x215

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
2. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
3. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
4. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
5. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
6. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
7. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
8. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
9. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
Post Your Comments:
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
Breaking Medicine News(10 mins):